RxDoctor Payments Data

Felix Sokolsky, MD

Internal Medicine · Gaithersburg, MDNPI 1386620706

Payments from drug & device makers

$2,453in general payments, 2019–2025

Across 90 payments — averaging $27.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$364
  • Novo Nordisk$283
  • AstraZeneca$265
  • Teva Pharmaceuticals USA, Inc.$235
  • Lundbeck LLC$214
  • Alkermes, Inc.$172
  • plus $922 from 16 others

What the payments were for

  • Food & beverage$2,453100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,453 in reported general payments places this provider in the 80th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$225,442
Medicare patients
506
Services billed
3,738

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban205$158,566
OzempicSemaglutide77$69,186
JardianceEmpagliflozin81$60,193
JanuviaSitagliptin Phosphate71$51,133
FarxigaDapagliflozin Propanediol39$42,799
XareltoRivaroxaban36$29,533
CreonLipase/Protease/Amylase14$16,234
LinzessLinaclotide23$12,851
MultaqDronedarone Hcl15$12,752
TradjentaLinagliptin23$12,552
Atorvastatin Calcium824$9,784
Breo ElliptaFluticasone/Vilanterol24$9,729
Metoprolol Succinate432$9,728
LunestaEszopiclone13$8,420
Repatha SureclickEvolocumab16$8,382

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Jentadueto$16$78,891115 claims
Novo NordiskOzempic$283$69,18677 claims
AstraZenecaFarxiga, Crestor$265$46,10952 claims
AbbVieCreon, Linzess, Synthroid$148$32,57387 claims
Johnson & JohnsonXarelto$28$29,53336 claims
GSKBreo Ellipta$104$9,72924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Gaithersburg

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →